Open Access UCL Research: Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women https://t.co/gf7lgp1BAM
I missed this really important study showing that population-based #BRCA testing is more cost-effective than any clinical criteria/family history-based strategy. #ovariancancer #breastcancer
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women https://t.co/muEO6oIsFR
"9.34 days’ life-expectancy gained. Clinical criteria/FH-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 more cost-effective than BRCA1/BRCA2 alone." https://t.co/1g0M21Qxh3
Finally seeing this 5wks post RRM "#PALB2 is the one that confers nonsyndromic quasi-Mendelian susceptibility to BC...for which equivalent interventions (RRM/breast MRI)... now offered to mutation carriers." Glad to see Antinou & Ramus on this @theNCI
There’s also a lot of interest in the potential utility of population screening for rare high risk mutations in genes like BRCA1/2 and PALB2. Cost-effectiveness, again in the UK setting: https://t.co/7YOZ6095SC 3/5
Population-level genomic screening identifies more pathogenic BRCA1/2 variants https://t.co/a53yOaHUiG
RT @NicoleKuderer: @bcsm this is now at least the 3. study with >800-1,000 patients that reveals that ~half the pts w germline predisposing…
RT @stacywgray: Totally agree @NicoleKuderer! Well said. https://t.co/QEXv6qsB2o
RT @NicoleKuderer: @bcsm this is now at least the 3. study with >800-1,000 patients that reveals that ~half the pts w germline predisposing…
Totally agree @NicoleKuderer! Well said.
@bcsm this is now at least the 3. study with >800-1,000 patients that reveals that ~half the pts w germline predisposing genes are missed based on clin family history. Population testing also appears to be cost-effective in most instances per @JNCI_Now
RT @NicoleKuderer: In case you missed it in @JNCI_Now: Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unse…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women | JNCI: Journal of the National Cancer Institute | Oxford Academic https://t.co/H8klySgEvw
RT @MNishigaki: 乳がん卵巣がんのゲノムスクリーニング最新費用対効果論文 J Natl Cancer Inst. 2018 Jan 18. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C,…
乳がん卵巣がんのゲノムスクリーニング最新費用対効果論文 J Natl Cancer Inst. 2018 Jan 18. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. https://t.co/NyUNEt1lNZ
Nova studie v JNCI ukazuje, ze geneticke testovani v siroke populaci jedincu je fakticky i cenove efektivnejsi nez omezeny skrinink v rizikovych rodinach. Opakovane se potvrzuje, ze populacni geneticka diagnostika se stane soucasti nasich zivotu, ktere bud
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patients with a personal or family history of the diseases: https://t.co/ygQWSYPLl2 https://t.co/m3KdxHylQA
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
Interesting comment on the utility of clinical genomics... more cost effective to use CG to screen patients than using personal history https://t.co/xSZYh4PR8D
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
Interesting statement here https://t.co/1SIhD7WXzs
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
Cost? https://t.co/PQY1DKzxVd
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patients with a personal or family history of the diseases: https://t.co/ygQWSYPLl2 https://t.co/BWvstF6njv
RT @caseofdees: De hele bevolking screenen op kankergenen is een kosteneffectievere manier om mensen die een hoog risico hebben te vinden d…
RT @caseofdees: De hele bevolking screenen op kankergenen is een kosteneffectievere manier om mensen die een hoog risico hebben te vinden d…
RT @caseofdees: De hele bevolking screenen op kankergenen is een kosteneffectievere manier om mensen die een hoog risico hebben te vinden d…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
Good news Mass screening using ‘gene’ is a more cost effective way targeting only high risk group. But is it more cost effective than the conventional screening? https://t.co/m8vW45VnL2
@JNCI_Now .https://t.co/qxlIL3aQwb Gene screening for cancer risk will likely prove very helpful but frought with social issues. New methods of screening much needed #Cancer #Health
RT @caseofdees: De hele bevolking screenen op kankergenen is een kosteneffectievere manier om mensen die een hoog risico hebben te vinden d…
RT @JNCI_Now: Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patien…
De hele bevolking screenen op kankergenen is een kosteneffectievere manier om mensen die een hoog risico hebben te vinden dan het screenen van alleen kankerpatiënten en mensen met belaste families..... https://t.co/qqTnzxnmLi
Screening the general population for cancer genes is a more cost effective way to detect people at risk than screening patients with a personal or family history of the diseases: https://t.co/ygQWSYPLl2 https://t.co/0xIWUb8w05
On #cancer screen:BRCA1/2+RAD51C/D+BRIP1+PALB2, but notBRCA1/2 alone, more cost-effective than clinical criteria/FH https://t.co/vnS9q3UcGS
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @HoulstonLab_ICR: The cost-effectiveness of #population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 #GeneticTesting in unselected w…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @HoulstonLab_ICR: The cost-effectiveness of #population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 #GeneticTesting in unselected w…
RT @HoulstonLab_ICR: The cost-effectiveness of #population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 #GeneticTesting in unselected w…
RT @HoulstonLab_ICR: The cost-effectiveness of #population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 #GeneticTesting in unselected w…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @HoulstonLab_ICR: The cost-effectiveness of #population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 #GeneticTesting in unselected w…
RT @HoulstonLab_ICR: The cost-effectiveness of #population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 #GeneticTesting in unselected w…
The cost-effectiveness of #population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 #GeneticTesting in unselected women. https://t.co/pXkEFJ6WAi @JNCI_Now @paulpharoah @clare__turnbull @HealthEconLSHTM
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 https://t.co/jRvVYSqaUW
RT @StephenPPovoski: An Interesting Concept: Cancer gene screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, & PALB2 mutations could be more…
An Interesting Concept: Cancer gene screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, & PALB2 mutations could be more cost effective in the unselected general female population than in just selected high-risk females. JNCI / Oxford Academic. https://t
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 https://t.co/dWdcgYN3mc
Had one done last week https://t.co/v39SPYtlih
#Cost #effectiveness of Population-Based #BRCA1, #BRCA2, #RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women | JNCI: Journal of the National Cancer Institute | Oxford Academic https://t.co/ewWT5ETRVb
RT @breastguide: Women should consider genetic testing for breast cancer genes regardless of family history https://t.co/bI5zANeU3c
Women should consider genetic testing for breast cancer genes regardless of family history https://t.co/bI5zANeU3c
RT @aftimosp: Cost-effectiveness data on population-based testing for germline breast and ovarian cancer-predisposing mutations. Patient co…
RT @aftimosp: Cost-effectiveness data on population-based testing for germline breast and ovarian cancer-predisposing mutations. Patient co…
Cost-effectiveness data on population-based testing for germline breast and ovarian cancer-predisposing mutations. Patient counselling remains very important https://t.co/TWAfWSbPtQ
RT @LguzzardiM: Cost-effectiveness of Population-Based #BRCA1, #BRCA2, #RAD51C, #RAD51D, #BRIP1, #PALB2 Mutation #GeneticTesting in Unselec…
In the news: Screening for breast cancer genes 'is cost-effective' . Is this true? Read about it @NHSChoices https://t.co/H1iCxTz7WA Link to paper https://t.co/6TQBDO4PXW Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mu
Recent advances in genomic medicine offer us the opportunity to deliver a new population-based predictive, preventive and personalised medicine strategy for cancer prevention https://t.co/mYBfXnRGD8
RT @LguzzardiM: Cost-effectiveness of Population-Based #BRCA1, #BRCA2, #RAD51C, #RAD51D, #BRIP1, #PALB2 Mutation #GeneticTesting in Unselec…
RT @LguzzardiM: Cost-effectiveness of Population-Based #BRCA1, #BRCA2, #RAD51C, #RAD51D, #BRIP1, #PALB2 Mutation #GeneticTesting in Unselec…
hmmm... #GCChat https://t.co/R6F1UHtYVH
RT @CharisEngMDPhD: Population-based screening for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is more cost-effective than screening ba…
RT @LguzzardiM: Cost-effectiveness of Population-Based #BRCA1, #BRCA2, #RAD51C, #RAD51D, #BRIP1, #PALB2 Mutation #GeneticTesting in Unselec…
RT @JNCI_Now: Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 htt…
Cancer gene screening is more cost effective in the general population than for high-risk groups: https://t.co/ygQWSYPLl2 https://t.co/Ispnf43ewi
RT @CharisEngMDPhD: Population-based screening for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is more cost-effective than screening ba…
Study (https://t.co/SJiCThaMDy) finds that testing the general population for OC/BC gene mutations is cost-effective. With the right support in place, should this be the way forward for health policy? https://t.co/FkWjOCKj2i #breastcancer #ovariancancer
RT @LguzzardiM: Cost-effectiveness of Population-Based #BRCA1, #BRCA2, #RAD51C, #RAD51D, #BRIP1, #PALB2 Mutation #GeneticTesting in Unselec…
RT @LguzzardiM: Cost-effectiveness of Population-Based #BRCA1, #BRCA2, #RAD51C, #RAD51D, #BRIP1, #PALB2 Mutation #GeneticTesting in Unselec…
RT @CharisEngMDPhD: Population-based screening for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is more cost-effective than screening ba…
RT @CharisEngMDPhD: Population-based screening for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is more cost-effective than screening ba…
Population-based screening for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is more cost-effective than screening based on clinical criteria/family history. https://t.co/dOUJWSAtlw @theNCI
@angelaraffle @eggersnsf @mgtmccartney @RichardLehman1 Authors suggest population-wide screening for #BRCA would be cost-effective > but what about false positives? https://t.co/KeSCL9mTHi